{"id":34332,"date":"2025-05-28T15:46:25","date_gmt":"2025-05-28T07:46:25","guid":{"rendered":"https:\/\/flcube.com\/?p=34332"},"modified":"2025-05-28T15:46:26","modified_gmt":"2025-05-28T07:46:26","slug":"salubris-pharmas-xinchaotuo-gains-nmpa-approval-for-primary-hypertension","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34332","title":{"rendered":"Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension"},"content":{"rendered":"\n

China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294<\/a>) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Xinchaotuo (sacubitril, allisartan) to treat primary hypertension. This marks the first domestically developed angiotensin receptor neprilysin inhibitor (ARNI) antihypertensive drug in China, with patent protection set to continue until 2037.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
Xinchaotuo, the world’s second ARNI eutectic drug following Entresto (sacubitril, valsartan), demonstrated significant and dose-dependent antihypertensive effects in a Phase III study. After 12 weeks of treatment with 240mg and 480mg once daily, the average decrease in systolic blood pressure was 25.07 mmHg and 28.22 mmHg, respectively. Stable blood pressure control was maintained until 52 weeks, indicating good long-term safety and tolerability.<\/p>\n\n\n\n

Ongoing Research<\/strong>
A Phase III study evaluating Xinchaotuo in chronic heart failure is currently underway, further exploring the drug’s potential in addressing this critical condition.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval…<\/p>\n","protected":false},"author":1,"featured_media":34333,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[108,15,335,1167],"class_list":["post-34332","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-high-blood-pressure","tag-product-approvals","tag-salubris-pharmaceuticals","tag-she-002294"],"yoast_head":"\nSalubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Xinchaotuo (sacubitril, allisartan) to treat primary hypertension. This marks the first domestically developed angiotensin receptor neprilysin inhibitor (ARNI) antihypertensive drug in China, with patent protection set to continue until 2037.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34332\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension\" \/>\n<meta property=\"og:description\" content=\"China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Xinchaotuo (sacubitril, allisartan) to treat primary hypertension. This marks the first domestically developed angiotensin receptor neprilysin inhibitor (ARNI) antihypertensive drug in China, with patent protection set to continue until 2037.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34332\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-28T07:46:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-28T07:46:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2813.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension\",\"datePublished\":\"2025-05-28T07:46:25+00:00\",\"dateModified\":\"2025-05-28T07:46:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332\"},\"wordCount\":154,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2813.webp\",\"keywords\":[\"High blood pressure\",\"Product approvals\",\"Salubris Pharmaceuticals\",\"SHE: 002294\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34332#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34332\",\"name\":\"Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2813.webp\",\"datePublished\":\"2025-05-28T07:46:25+00:00\",\"dateModified\":\"2025-05-28T07:46:26+00:00\",\"description\":\"China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Xinchaotuo (sacubitril, allisartan) to treat primary hypertension. This marks the first domestically developed angiotensin receptor neprilysin inhibitor (ARNI) antihypertensive drug in China, with patent protection set to continue until 2037.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34332\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2813.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2813.webp\",\"width\":1080,\"height\":608,\"caption\":\"Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34332#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension - Insight, China's Pharmaceutical Industry","description":"China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Xinchaotuo (sacubitril, allisartan) to treat primary hypertension. This marks the first domestically developed angiotensin receptor neprilysin inhibitor (ARNI) antihypertensive drug in China, with patent protection set to continue until 2037.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34332","og_locale":"en_US","og_type":"article","og_title":"Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension","og_description":"China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Xinchaotuo (sacubitril, allisartan) to treat primary hypertension. This marks the first domestically developed angiotensin receptor neprilysin inhibitor (ARNI) antihypertensive drug in China, with patent protection set to continue until 2037.","og_url":"https:\/\/flcube.com\/?p=34332","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-28T07:46:25+00:00","article_modified_time":"2025-05-28T07:46:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2813.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34332#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34332"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension","datePublished":"2025-05-28T07:46:25+00:00","dateModified":"2025-05-28T07:46:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34332"},"wordCount":154,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34332#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2813.webp","keywords":["High blood pressure","Product approvals","Salubris Pharmaceuticals","SHE: 002294"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34332#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34332","url":"https:\/\/flcube.com\/?p=34332","name":"Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34332#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34332#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2813.webp","datePublished":"2025-05-28T07:46:25+00:00","dateModified":"2025-05-28T07:46:26+00:00","description":"China-based Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its Xinchaotuo (sacubitril, allisartan) to treat primary hypertension. This marks the first domestically developed angiotensin receptor neprilysin inhibitor (ARNI) antihypertensive drug in China, with patent protection set to continue until 2037.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34332#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34332"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34332#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2813.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2813.webp","width":1080,"height":608,"caption":"Salubris Pharma's Xinchaotuo Gains NMPA Approval for Primary Hypertension"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34332#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Salubris Pharma’s Xinchaotuo Gains NMPA Approval for Primary Hypertension"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2813.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34332"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34332\/revisions"}],"predecessor-version":[{"id":34334,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34332\/revisions\/34334"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34333"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}